What is EVerZom?
Founded in 2019, EVerZom operates at the intersection of biotechnology and regenerative medicine. The company has developed a proprietary platform that manages the entire technological value chain of exosome production, a significant differentiator in the current biotech landscape. By focusing on digestive tissue healing, fistula treatment, and organ regeneration, EVerZom addresses high-unmet medical needs. Its lead drug candidates have demonstrated substantial potential in preclinical trials, specifically regarding the acceleration of tissue repair and the modulation of inflammatory responses. The company's integrated approach to exosome manufacturing allows for scalable production, positioning it as a formidable player in the evolving field of cell-free regenerative therapies.
How much funding has EVerZom raised?
EVerZom has raised a total of $1.3M across 1 funding round:
Unspecified
$1.3M
Unspecified (2020): $1.3M, investors not publicly disclosed
Key Investors in EVerZom
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for EVerZom?
With the infusion of this major enterprise-level funding, EVerZom is poised to scale its operational capabilities and deepen its clinical pipeline. The strategic roadmap involves advancing its primary candidates for Crohn's fistula and organ regeneration through rigorous regulatory milestones. Furthermore, the company is actively seeking collaborative partnerships to co-develop its exosome platform across diverse therapeutic indications. By leveraging its proprietary production technology, EVerZom aims to establish a dominant market position, transforming the therapeutic landscape for patients suffering from chronic digestive and organ-related conditions. The focus remains on translating preclinical success into tangible clinical outcomes, ensuring the company remains at the forefront of the regenerative medicine sector.
See full EVerZom company page
